USPTO issued patent US12594344B2 to China Medical University covering a method for producing exosomes at scale using cyclic tensile bioreactor stimulation of cells, combined with exosome compositions having anti-HLA-G protein for targeted cancer therapy delivery. The patent (application no. 18060966, filed December 2, 2022) includes 10 claims and names 9 inventors. CPC classifications indicate application to A61K 47/6901 (drug conjugates), C07K 16/2833 (antibodies), and C12N 5/0686 (cell-based therapies).\n\nPharmaceutical and biotechnology companies developing exosome-based drug delivery systems should review this patent for potential licensing needs or freedom-to-operate considerations. Academic medical centers and research institutions conducting exosome research for cancer therapeutics should assess whether their methods fall within the granted claim scope. Patent grants establish enforceable exclusive rights but do not impose compliance deadlines or penalties on third parties.